Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor ?B, osteoprotegerin, and receptor activator of nuclear factor ?B ligand-Reference-Cited by-同舟云学术

Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor ?B, osteoprotegerin, and receptor activator of nuclear factor ?B ligand

Published:2004-12 Issue:12 Volume:50 Page:3831-3843
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis Rheum

Author:

Lee Chang-Keun,Lee Eun Young,Chung Son Mi,Mun Se Hwan,Yoo Bin,Moon Hee-Bom

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Reference34 articles.

1. Collagenase at Sites of Cartilage Erosion in the Rheumatoid Joint

2. Cathepsin B in synovial cells at the site of joint destruction in rheumatoid arthritis

3. The human osteoclast precursor circulates in the monocyte fraction.

4. A New Mechanism of Bone Destruction in Rheumatoid Arthritis: Synovial Fibroblasts Induce Osteoclastogenesis

5. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Prospects in Rheumatoid Arthritis: Pathophysiology, Genetics, and Treatments;Recent Advances in Anti-Infective Drug Discovery;2024-04

2. The effects of hydroxychloroquine-induced oxidative stress on fracture healing in an experimental rat model;Joint Diseases and Related Surgery;2023-11-30

3. In vitro osteoclastogenesis in autoimmune diseases – Strengths and pitfalls of a tool for studying pathological bone resorption and other disease characteristics;Heliyon;2023-11

4. Sulfasalazine promotes myogenic differentiation via increasing of fast myosin heavy chain isoforms;2023-08-16

5. Association between disease‐modifying antirheumatic drugs and bone turnover biomarkers;International Journal of Rheumatic Diseases;2022-12-27